Efaroxan

Chemical compound
  • none
Legal statusLegal status
  • In general: uncontrolled
Identifiers
  • 2-(2-ethyl-2,3-dihydro-1-benzofuran-2-yl)-4,5-dihydro-1H-imidazole
CAS Number
  • 89197-32-0 checkY
PubChem CID
  • 72016
ChemSpider
  • 65015 checkY
UNII
  • G00490L21H
ChEMBL
  • ChEMBL57895 checkY
CompTox Dashboard (EPA)
  • DTXSID8045149 Edit this at Wikidata
Chemical and physical dataFormulaC13H16N2OMolar mass216.284 g·mol−13D model (JSmol)
  • Interactive image
  • N\1=C(\NCC/1)C3(Oc2ccccc2C3)CC
InChI
  • InChI=1S/C13H16N2O/c1-2-13(12-14-7-8-15-12)9-10-5-3-4-6-11(10)16-13/h3-6H,2,7-9H2,1H3,(H,14,15) checkY
  • Key:RATZLMXRALDSJW-UHFFFAOYSA-N checkY
  (verify)

Efaroxan is an α2-adrenergic receptor antagonist[1] and antagonist of the imidazoline receptor.

Synthesis

Synthesis (Cmp#13):[2] Revised:[3][4]

The Darzens reaction between 2-fluorobenzaldehyde [57848-46-1] (1) and Ethyl 2-bromobutyrate [533-68-6] (2) gives ethyl 2-ethyl-3-(2-fluorophenyl)oxirane-2-carboxylate, CID:100942311 (3). A catalytic hydrogenation over Pd/C would give ethyl 2-[(2-fluorophenyl)methyl]-2-hydroxybutanoate, CID:77591056 (4). Saponification of the ester then gives 2-[(2-Fluorophenyl)methyl]-2-hydroxybutanoic acid, CID:53869347 (5). Treatment with 2 molar equivalents of sodium hydride apparently gives 2-Ethyl-2,3-dihydrobenzofuran-2-carboxylic acid [111080-50-3] (6). Treatment of the carboxylic acid with thionyl chloride then gives the acid chloride and subsequent treatment of this with ethylenediamine in the presence of trimethylaluminium completed the synthesis of Efaroxan (8).

See also

References

  1. ^ Chopin P, Colpaert FC, Marien M (February 1999). "Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway". J. Pharmacol. Exp. Ther. 288 (2): 798–804. PMID 9918591.
  2. ^ Chapleo, Christopher B.; Myers, Peter L.; Butler, Richard C. M.; Davis, John A.; Doxey, John C.; Higgins, Stanley D.; Myers, Malcolm; Roach, Alan G.; Smith, Colin F. C. (1984). ".alpha.-Adrenoceptor reagents. 2. Effects of modification of the 1,4-benzodioxan ring system on .alpha.-adrenoreceptor activity". Journal of Medicinal Chemistry 27 (5): 570–576. doi:10.1021/jm00371a003.
  3. ^ Mayer, P.; Brunel, P.; Imbert, T. (1999). "A new efficient synthesis of efaroxan". Bioorganic & Medicinal Chemistry Letters 9 (20): 3021–3022. doi:10.1016/S0960-894X(99)00531-4.
  4. ^ Couture, K.; Gouverneur, V.; Mioskowski, C. (1999). "A new approach to the synthesis of efaroxan". Bioorganic & Medicinal Chemistry Letters 9 (20): 3023–3026. doi:10.1016/S0960-894X(99)00530-2.

External links

  • Media related to Efaroxan at Wikimedia Commons
  • v
  • t
  • e
α1
Agonists
Antagonists
α2
Agonists
Antagonists
β
Agonists
Antagonists
  • See also: Receptor/signaling modulators
  • Dopaminergics
  • Serotonergics
  • Monoamine reuptake inhibitors
  • Monoamine releasing agents
  • Monoamine metabolism modulators
  • Monoamine neurotoxins
  • v
  • t
  • e
IRTooltip Imidazoline receptor
See also: Receptor/signaling modulators


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e